{
    "root": "3d8f2c35-1aec-424f-9618-a59770ecd7f5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Famotidine",
    "value": "20250401",
    "ingredients": [
        {
            "name": "Famotidine",
            "code": "5QZO15J2Z8"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "Ferric Oxide Yellow",
            "code": "EX438O2MRT"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "Polyethylene Glycol 400",
            "code": "B697894SGQ"
        },
        {
            "name": "Silicon Dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "Starch, Corn",
            "code": "O8232NY3SJ"
        },
        {
            "name": "Talc",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:\n                  • active duodenal ulcer (DU).\n                  • active gastric ulcer (GU).\n                  • symptomatic nonerosive gastroesophageal reflux disease (GERD).\n                  • erosive esophagitis due to GERD, diagnosed by biopsy. \n                  Famotidine tablets are indicated in adults for the:\n                  • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).\n                  • reduction of the risk of duodenal ulcer recurrence.",
    "contraindications": "Indication Recommended Dosage ( Error! Hyperlink reference not valid. ) Adult and Pediatric Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice daily Active GastricUlcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or40 mg twice daily Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily • See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. ( Error! Hyperlink reference not valid. , Error! Hyperlink reference not valid. ) Administration ( Error! Hyperlink reference not valid. ): Take once daily before bedtime or twice daily in the morning and before bedtime with or without food.",
    "warningsAndPrecautions": "Famotidine tablets USP, 20 mg are yellow, film-coated, round shaped tablets with  ‘C’ over 119’ \n                  on one side and plain on other side and are supplied in bottles of 30 and 90 count. \n                   Bottles of 30 NDC 82804-194-30\n                   Bottles of 90 NDC 82804-194-90\n                  \n                     Storage\n                  \n                  Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. \n                  Dispense in a USP tight, light-resistant container.",
    "adverseReactions": "Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H2) receptor antagonists."
}